questionText: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 October 2025 to Question 83371 on Abiraterone: Finance, what steps he is taking to secure recurrent budget allocation for abiraterone for use in cases of high-risk non-metastatic prostate cancer.
answerText: Abiraterone is not licensed for use in the treatment of high-risk, non-metastatic hormone-sensitive prostate cancer, and as such, cannot be evaluated by the National Institute for Health and Care Excellence (NICE) for routine use on the National Health Se...
heading: Abiraterone: Finance